Page last updated: 2024-11-10

npc 17731

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

NPC 17731: bradykinin receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3081308
MeSH IDM0193823

Synonyms (10)

Synonym
arg-arg-pro-hyp-gly-phe-ser-hype (transpropyl)-oic-arg
147267-10-5
npc-17731
bradykinin, n2-d-arginyl-3-(trans-4-hydroxy-l-proline)-7-(trans-4-propoxy-d-proline)-8-(l-(2alpha,3abeta,7abeta)-octahydro-1h-indole-2-carboxylic acid)-
gtpl657
d-arg[hyp3,trans-4-propoxy-d-proline(transpropyl)7,oic8]bradykinin
npc17731
npc 17731
(4s)-2-(1-((s)-1-(d-arginyl-l-arginyl)pyrrolidin-2-yl)-4-guanidino-1-oxobutan-2-yl)-5-hydroxy-4-((2s)-2-(2-((2s)-4-hydroxypyrrolidine-2-carboxamido)acetamido)-3-phenylpropanamido)-3-oxo-2-((3as,7as)-n-((2r,4s)-4-propoxypyrrolidine-2-carbonyl)octahydro-1h-
Q27088022

Research Excerpts

Overview

NPC 17731 proved to be a safe, effective specific bradykinin receptor antagonist in both cutaneous and airway challenges.

ExcerptReferenceRelevance
"NPC 17731 proved to be a safe, effective specific bradykinin receptor antagonist in both cutaneous and airway challenges."( A bradykinin antagonist inhibits both bradykinin- and the allergen-induced airway response in primates.
Harris, KE; Hogan, MB; Patterson, R; Protter, AA, 1997
)
1.02

Actions

ExcerptReferenceRelevance
"NPC 17731 was able to inhibit the antigen-induced airway response in the primate."( A bradykinin antagonist inhibits both bradykinin- and the allergen-induced airway response in primates.
Harris, KE; Hogan, MB; Patterson, R; Protter, AA, 1997
)
1.02

Dosage Studied

ExcerptRelevanceReference
" To determine whether kinin production is required for the development of airway hyperresponsiveness induced by cationic proteins, dose-response curves to methacholine were constructed before and 1 h after intratracheal instillation of either MBP or poly-L-lysine (100 micrograms)."( Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation.
Ackerman, SJ; Burch, R; Coyle, AJ; Irvin, CG; Proud, D, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1346495Human B1 receptor (Bradykinin receptors)1997The Journal of biological chemistry, Jan-03, Volume: 272, Issue:1
The sixth transmembrane domains of the human B1 and B2 bradykinin receptors are structurally compatible and involved in discriminating between subtype-selective agonists.
AID1346473Human B2 receptor (Bradykinin receptors)1997The Journal of biological chemistry, Jan-03, Volume: 272, Issue:1
The sixth transmembrane domains of the human B1 and B2 bradykinin receptors are structurally compatible and involved in discriminating between subtype-selective agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's23 (88.46)18.2507
2000's3 (11.54)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.81 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]